Ensign Peak Advisors
LLY icon

Ensign Peak Advisors’s Eli Lilly LLY Stock Holding History

Ensign Peak Advisors’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07B Buy
895,262
+47,059
+6% +$48.1M 1.77% 10
2026
Q1 		$780M Buy
848,203
+10,546
+1% +$10.7M 1.45% 11
2025
Q4 		$900M Buy
837,657
+210,639
+34% +$201M 1.59% 10
2025
Q3 		$478M Sell
627,018
-242,907
-28% -$181M 0.78% 17
2025
Q2 		$678M Sell
869,925
-25,975
-3% -$20.2M 1.16% 11
2025
Q1 		$740M Buy
895,900
+16,762
+2% +$13.9M 1.42% 10
2024
Q4 		$679M Buy
879,138
+2,726
+0.3% +$2.26M 1.21% 13
2024
Q3 		$776M Sell
876,412
-15,503
-2% -$13.9M 1.37% 10
2024
Q2 		$808M Sell
891,915
-35,339
-4% -$28.3M 1.48% 9
2024
Q1 		$721M Buy
927,254
+221,327
+31% +$158M 1.32% 10
2023
Q4 		$411M Buy
705,927
+117,708
+20% +$68.7M 0.81% 18
2023
Q3 		$316M Sell
588,219
-288,166
-33% -$148M 0.67% 30
2023
Q2 		$411M Buy
876,385
+167,426
+24% +$70.2M 0.83% 19
2023
Q1 		$243M Buy
708,959
+290,645
+69% +$98M 0.53% 45
2022
Q4 		$153M Buy
418,314
+30,207
+8% +$10.7M 0.34% 74
2022
Q3 		$125M Buy
388,107
+109,602
+39% +$34.7M 0.31% 75
2022
Q2 		$90.3M Sell
278,505
-221,910
-44% -$66.6M 0.21% 105
2022
Q1 		$143M Sell
500,415
-143,781
-22% -$37M 0.29% 79
2021
Q4 		$178M Sell
644,196
-33,543
-5% -$8.5M 0.34% 71
2021
Q3 		$157M Sell
677,739
-327,396
-33% -$80.8M 0.33% 81
2021
Q2 		$231M Sell
1,005,135
-44,851
-4% -$9.01M 0.47% 54
2021
Q1 		$196M Buy
1,049,986
+278,594
+36% +$54.5M 0.42% 60
2020
Q4 		$130M Sell
771,392
-75,535
-9% -$11.3M 0.3% 85
2020
Q3 		$125M Buy
846,927
+31,871
+4% +$4.93M 0.32% 72
2020
Q2 		$134M Buy
815,056
+549,775
+207% +$84.4M 0.36% 64
2020
Q1 		$36.8M Sell
265,281
-31,253
-11% -$4.29M 0.12% 131
2019
Q4 		$39M Buy
+296,534
New +$34.4M 0.1% 166

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ensign Peak Advisors's LLY Position: Q2 2026 in Review

Ensign Peak Advisors increased its Eli Lilly (LLY) stake by 5.5% in Q2 2026, buying an estimated $48.1M and bringing the position to 895,262 shares worth $1.07B. The position accounts for 1.77% of the portfolio, ranked #10.

Ensign Peak Advisors first reported a position in LLY in Q4 2019 and has held it in 27 quarters since. 4,593 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Ensign Peak Advisors held 895,262 shares of Eli Lilly worth $1.07B as of Q2 2026.
  • Ensign Peak Advisors bought 47,059 Eli Lilly shares in Q2 2026, an estimated $48.1M.
  • Eli Lilly made up 1.77% of Ensign Peak Advisors's portfolio in Q2 2026, its #10 holding.
  • Ensign Peak Advisors first reported a position in Eli Lilly in Q4 2019 and has held it in 27 quarters since.
  • 4,593 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.